US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

The Aaron's Company, Inc.

10.09

+0.0000

Volume:- -

Turnover:- -

Market Cap:309.89M

PE:-7.25

High:10.09

Open:10.09

Low:10.09

Close:10.09

Loading ...

Overview Company News Filings

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Alterity Therapeutics reports new data from ATH434 Phase 2 trial at AAN meeting

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

Quest Diagnostics Launches New AD-Detect™ Blood Test to Aid in Confirming Alzheimer's Disease

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis

Cerevance Presents Positive Results from Phase 1 Study of CVN293 at American Academy of Neurology 2025 Annual Meeting

Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome

NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting

argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP

Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting

Xenon Pharmaceuticals to Present Promising Azetukalner Data at AAN 2025

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025

Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AAN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AAN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAN\",,,,,undefined,":{"symbol":"AAN","market":"US","secType":"STK","nameCN":"The Aaron's Company, Inc.","latestPrice":10.09,"timestamp":1745524800000,"preClose":10.09,"halted":0,"volume":0,"delay":0,"floatShares":29872074,"shares":30712772,"eps":-1.391109,"marketStatus":"Closed","change":0,"latestTime":"04-24 16:00:00 EDT","open":10.09,"high":10.09,"low":10.09,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.391109,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745568000000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":10.09,"dividendRate":0.049554,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAN\",,,,,undefined,":{"symbol":"AAN","floatShares":29872074,"roa":"2.18%","roe":"-6.22%","lyrEps":0.091721,"shares":30712772,"dividePrice":0.5,"high":10.09,"amplitude":0,"preClose":10.09,"low":10.09,"week52Low":6.622,"pbRate":"0.47","psRate":"0.15","week52High":11.9,"institutionHeld":0.9259,"latestPrice":10.09,"eps":-1.391109,"divideRate":0.049554,"volume":0,"delay":0,"ttmEps":-1.391109,"open":10.09,"prevYearClose":10.88},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527015710","title":"Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2527015710","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527015710?lang=en_us&edition=fundamental","pubTime":"2025-04-14 20:15","pubTimestamp":1744632900,"startTime":"0","endTime":"0","summary":"Findings Further Support the Safety Profile and Immunomodulatory Effects of ADI-100, Adimune’s Lead Therapeutic Candidate for Autoimmune Diseases. The independent study, led by Dr. Sean Pittock and Dr. Charles Howe of the Mayo Clinic’s neuroimmunology team, confirmed that ADI-100 induces immune tolerance to glutamic acid decarboxylase —a key autoantigen implicated in multiple autoimmune conditions, including type 1 diabetes, stiff person syndrome, cerebellar ataxia, and autoimmune epilepsy.\"These results mark an important milestone not only for Adimune’s platform but also for Aditxt’s broader vision of transforming the way we approach autoimmune diseases,\" said Amro Albanna, co-founder and CEO of Aditxt. \"We believe that autoimmunity represents one of the most underserved and challenging areas of medicine. ADI-100’s potential ability to restore immune tolerance without broad immunosuppression is a meaningful step toward safer, more targeted treatments.\". Immune Modulation at the Cellul","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aditxt-subsidiary-adimune-announces-positive-121500858.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4082","LU0006061336.USD","LU0310799852.SGD","LU0211328371.USD","BAX","BK4584","LU2098885051.SGD","LU1303367103.USD","LU0072461881.USD","ADTX","BK4139","BK4007","BK4178","BK4504","LU1267930490.SGD","BK4588","LU0211327993.USD","EVFM","BK4585","LU0162691827.USD","AAN"],"gpt_icon":0},{"id":"2526568284","title":"Alterity Therapeutics reports new data from ATH434 Phase 2 trial at AAN meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2526568284","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526568284?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:45","pubTimestamp":1744285557,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics (ATHE) announced that new presentations related to its Multiple System Atrophy program were delivered at the American Academy...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-reports-new-data-from-ath434-phase-2-trial-at-aan-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-reports-new-data-from-ath434-phase-2-trial-at-aan-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AAN","BK4178","BK4139","BK4007","ATHE","LENZ"],"gpt_icon":0},{"id":"2526550996","title":"Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2526550996","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526550996?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:35","pubTimestamp":1744284900,"startTime":"0","endTime":"0","summary":"– Clinically Meaningful Efficacy Observed on Multiple Assessments –。– Confirmed Target Engagement with Reduced Iron Signal in MSA Affected Brain Regions –。Type: Oral Presentation Title: Topline Data from a Randomized, Double Blind, Placebo Controlled Phase 2 Study of ATH434 in Multiple System AtrophyPresenter: Daniel Claassen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical CenterSummary: The oral presentation produced additional data on Alterity’s ATH434-201 Phase 2 clinical trial. Overall, the study results support continued advancement of ATH434 for the treatment of MSA. The imaging outcomes in n=61 participants indicate a heterogeneous localization of pathology and evidence that ATH434 reduces the iron signal in MSA affected brain regions. The clinical analysis included 71 patients who had at least one-post baseline UMSARS I assessment. The data showed that on the modified UMSARS I rating scale, ATH434 demonstrated a clinically significant treatment effect versu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alterity-therapeutics-presents-encouraging-data-113500434.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4178","LU1923622291.USD","ATH.AU","LU2211815571.USD","LU0728928796.USD","LU1815336091.USD","LU0757428866.USD","BK4007","BK4107","TUG","LU2125909916.SGD","AFG","LU2125909759.SGD","BK4143","LENZ","BK4139","MSA","ATHE","BK4117","AAN","LU0053671581.USD"],"gpt_icon":0},{"id":"2526366907","title":"NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2526366907","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526366907?lang=en_us&edition=fundamental","pubTime":"2025-04-09 20:30","pubTimestamp":1744201800,"startTime":"0","endTime":"0","summary":"New miRNA findings unveiled at the AAN, reveal key biological mechanisms behind PrimeC's clinical benefit in ALS.CAMBRIDGE, Mass., April 9, 2025 /PRNewswire/ --NeuroSense Therapeutics, Ltd. , a leading clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, today announced promising new findings from its Phase 2b PARADIGM clinical trial. The data highlights the significant impact of PrimeC, the company's investigational therapy for the treatment of amyotrophic lateral sclerosis , on microRNA  modulation.Represent an important development in understanding how the therapy may slow disease progression in people living with ALS.This research, conducted in collaboration with Prof. Noam Shomron of Tel Aviv University's Facultyof Medical and Health Sciences, a leader in microRNA research and functional genomics, was presented yesterday by Jeffrey Rosenfeld, M.D., Ph.D., Professor of Neurology and Associate Chairman of Neurology at Loma Lind","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/neurosense-therapeutics-announces-transformative-phase-123000446.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurosense-therapeutics-announces-transformative-phase-123000446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4178","BK4139","NRSN","BK4007","AAN","NRSNW"],"gpt_icon":0},{"id":"2526680573","title":"Quest Diagnostics Launches New AD-Detect™ Blood Test to Aid in Confirming Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2526680573","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526680573?lang=en_us&edition=fundamental","pubTime":"2025-04-09 19:53","pubTimestamp":1744199580,"startTime":"0","endTime":"0","summary":"In an oral presentation at the 2025 AAN Annual Meeting, Quest scientists presented data suggesting the test can accurately assess Alzheimer's disease pathology withgreater than 90% sensitivity and specificity. SECAUCUS, N.J., April 9, 2025 /PRNewswire/ -- Quest Diagnostics , a leader in diagnostic information services, including advanced diagnostics for brain health, today announced the launch of a new laboratory blood test designed to help physicians confirm amyloid brain pathology due to Alzheimer's disease  in patients with mild cognitive impairment  or dementia.In an oral presentation given this week at the American Academy of Neurology 's Annual Meeting in San Diego, Quest researchers presented data demonstrating that the new test would have a positive predictive value  of 89% and negative predictive value  of 89% in a population with mild cognitive impairment when the test cut offs were set at 91% sensitivity and 91% specificity. The addition of ApoE, a genetic risk marker, furth","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/quest-diagnostics-launches-ad-detect-115300603.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/quest-diagnostics-launches-ad-detect-115300603.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1854104046.USD","BK4598","LU0128526141.USD","LU0029874061.USD","MCI","AB","AAN","BK4583","BK4135","BK4588","BK4178","BK4567","LU1854103824.USD","BK4196","DGX","BK4585","BK4590"],"gpt_icon":0},{"id":"2526840473","title":"Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2526840473","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526840473?lang=en_us&edition=fundamental","pubTime":"2025-04-09 04:05","pubTimestamp":1744142700,"startTime":"0","endTime":"0","summary":"Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS Disease Education C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057993/0/en/Annexon-Highlights-Pivotal-Data-on-First-Potential-Targeted-Therapy-for-Guillain-Barr%C3%A9-Syndrome-GBS-and-Showcases-New-GBS-Education-Campaign-at-American-Academy-of-Neurology-AAN-20.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANNX","BK4117","TUG","BK4178","AAN","BK4107","GBSG","BK4139","AFG"],"gpt_icon":0},{"id":"2526846138","title":"Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2526846138","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526846138?lang=en_us&edition=fundamental","pubTime":"2025-04-09 01:11","pubTimestamp":1744132260,"startTime":"0","endTime":"0","summary":"Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis. Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosis. Tolebrutinib has the potential to be the first therapy to modulate immunologic drivers of chronic inflammation behind the blood–brain barrier, a key driver of disability accumulation in MS. Tolebrutinib is being evaluated under priority review in the US with a target action date of 28 September 2025; regulatory submission dossieris under review in the EU with a decision expected in Q1 2026. The HERCULES data demonstrated that tolebrutinib delayed the time to onset of 6-month confirmed disability progression  by 31% compared to placebo . Additionally, results from the GEMINI 1 and 2 phase 3 studies, evaluating tolebrutinib in people with relapsing multiple sclerosis  were also published in NEJM and presented today during ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/press-release-tolebrutinib-phase-3-171100646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SNY","BK4007","BK4178","ARR","CDP","IE00BFXG1179.USD","BK4110","BK4585","BK4588","BK4223","AAN"],"gpt_icon":0},{"id":"2525814141","title":"Cerevance Presents Positive Results from Phase 1 Study of CVN293 at American Academy of Neurology 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2525814141","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525814141?lang=en_us&edition=fundamental","pubTime":"2025-04-08 23:00","pubTimestamp":1744124400,"startTime":"0","endTime":"0","summary":"CVN293 was generally well-tolerated in healthy volunteers with evidence of robust brain penetration, supporting utility of KCNK13 inhibitors for neurodegenerative diseases characterized by neuroinflam","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057821/0/en/Cerevance-Presents-Positive-Results-from-Phase-1-Study-of-CVN293-at-American-Academy-of-Neurology-2025-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","BK4135","AFG","BK4117","CSF","BK4178","AAN","BK4107"],"gpt_icon":0},{"id":"2525892015","title":"Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2525892015","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525892015?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:05","pubTimestamp":1744113900,"startTime":"0","endTime":"0","summary":"Data to be Presented at the Hot Topics in Child Neurology Podium Presentation Session at the American Academy of Neurology Annual Meeting. PLYMOUTH MEETING, Pa., April 08, 2025----Harmony Biosciences Holdings, Inc.  today announced the presentation of updated data from its Open-Label Extension  study  evaluating the safety and effectiveness of ZYN002 in children, adolescents, and adults with Fragile X syndrome . The data showed clinically meaningful improvements in irritability-related symptoms prevalent in individuals with FXS. There are currently no U.S. Food & Drug Administration  approved treatments for FXS.\"The acceptance of our Fragile X syndrome OLE data as a podium presentation at AAN underlines the significant unmet need in FXS, and the potential for ZYN002 to become the first-and-only approved treatment for this condition,\" said Kumar Budur, MD, MS, Chief Medical and Scientific Officer at Harmony Biosciences. \"These data are encouraging as we prepare for the topline data read","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/harmony-biosciences-presents-promising-open-120500495.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AAN","HRMY","BK4007","FXS","BK4178"],"gpt_icon":0},{"id":"2525289956","title":"NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2525289956","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525289956?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:00","pubTimestamp":1744113600,"startTime":"0","endTime":"0","summary":"NeuroPace RNS System   NeuroPace RNS System   Three-year data from the largest FDA-reviewed prospective neuromodulation study of safety and effectiveness in drug-resistant focal epilepsy1Long-term sei","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057542/0/en/NeuroPace-Announces-Data-From-a-Long-Term-Post-Approval-Study-of-the-RNS-System-in-Focal-Epilepsy-at-the-2025-AAN-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAN","NPCE","POST"],"gpt_icon":0},{"id":"2525501835","title":"argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP","url":"https://stock-news.laohu8.com/highlight/detail?id=2525501835","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525501835?lang=en_us&edition=fundamental","pubTime":"2025-04-08 13:00","pubTimestamp":1744088400,"startTime":"0","endTime":"0","summary":"ADAPT-NXT data demonstrate consistent, sustained disease control across dosing schedules, further supporting individualized VYVGART dosing for gMG patients ADHERE+ oral presentation features long-term","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057307/0/en/argenx-Highlights-VYVGART-Data-at-AAN-2025-Setting-New-Standard-in-Sustained-Efficacy-and-Improved-Quality-of-Life-Measures-for-Patients-Living-with-gMG-and-CIDP.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMP","LU2500361329.USD","BK4156","AAN","BK4178","BK4208","BK4124","LU2637428348.USD","LU1894683348.USD","CMS","BK4585","LU2346227817.USD","BK4588","LU1894683264.USD"],"gpt_icon":0},{"id":"2525301085","title":"Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2525301085","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525301085?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:00","pubTimestamp":1744027200,"startTime":"0","endTime":"0","summary":"- Analysis of RISE-PD presented at AAN 2025 showed CREXONT treatment significantly improved patients’ Parkinson’s Disease Sleep Scale-2  total and sub-scale scores. - Treatment with CREXONT also resulted in significantly more patients waking up in an \"On\" state compared to immediate-release CD/LD patients, as part of separate study analysis. BRIDGEWATER, N.J., April 07, 2025----Amneal Pharmaceuticals, Inc.  , a global biopharmaceutical company, today announced a new analysis of the pivotal RISE-PD Phase 3 study showed that patients who successfully converted to CREXONT from immediate release  carbidopa/levodopa  experienced statistically significant improvements in sleep quality. These improvements were measured by their Parkinson’s Disease Sleep Scale-2  total scores, showing a mean difference of -2.35 .A separate analysis of Hauser diary entries, which is a commonly used PD symptom tracking tool, from patients who completed the RISE-PD study will also be presented at AAN. Treatment w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amneal-announces-data-phase-3-120000084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","LU0256863811.USD","PD","BK4007","CNS","BK4135","AMRX","BK4116","LU1978683503.SGD","LU0256863902.USD","AAN","LU1169590202.USD","BK4585","BK4588","BK4023","CD","BK4178","LU0124384867.USD","LU1169589451.USD","IR","LU0417517546.SGD","SG9999001440.SGD"],"gpt_icon":0},{"id":"2525017530","title":"Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2525017530","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525017530?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:00","pubTimestamp":1744027200,"startTime":"0","endTime":"0","summary":"Presentation Title: \"Translating IGHMBP2 Variants with a CMT2S Patient-specific Organ-on-a-chip Model: Personalized Medicine ASO-based Therapeutic Rescue\" Poster Presentation Session: P-12 Poster Number: 11-017 Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics. This poster describes the data around a novel breakthrough therapeutic  customized to a specific genetic mutation of a patient with Charcot-Marie-Tooth disease type 2S . The effects of VCA-894A were confirmed in Hesperos' Human-on-a-Chipneuromuscular junction model with patient-derived cells where VCA-894A demonstrated significant improvements in neuromuscular function, including reduced muscle fatigue and improved synaptic transmission between motor neurons and skeletal muscle myotubes. The use of a microphysiological system to evaluate the effects of a genetically tailored treatment represents a significant advancement in precision medicine and the use of human relevant methods of evaluation.VCA-894A has been granted an","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/vanda-pharmaceuticals-announces-presentation-2025-120000402.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vanda-pharmaceuticals-announces-presentation-2025-120000402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VNDA","AAN","BK4139","BK4178"],"gpt_icon":0},{"id":"2525571856","title":"Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2525571856","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525571856?lang=en_us&edition=fundamental","pubTime":"2025-04-05 21:00","pubTimestamp":1743858000,"startTime":"0","endTime":"0","summary":"SAN DIEGO and NEW HAVEN, Conn., April 5, 2025 /PRNewswire/ --Biohaven Ltd. announced today that it will present 13 abstracts at the 2025 American Academy of Neurology  Annual Meeting, taking place from April 5 to April 9, 2025 in San Diego, California. The presentations highlight Biohaven's innovative neuroscience pipeline across multiple early and late-stage development programs including Kv7 ion channel modulation, extracellular protein degradation, TRPM3 antagonism, TYK2/JAK1 inhibition, and glutamate modulation.Irfan Qureshi, M.D., Chief Medical Officer of Biohaven, commented, \"We are excited to highlight our clinical and scientific progress at the AAN Annual Meeting, including 3 oral presentations and 10 poster presentations, emphasizing Biohaven's innovation, leadership and commitment to developing potential first-in-class therapies for debilitating neurological disorders with inadequate or no treatment options. The team at Biohaven has been working urgently to advance our next-g","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/biohaven-presents-data-across-innovative-130000816.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biohaven-presents-data-across-innovative-130000816.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4107","SCA","AAN","BK4117","BK4139","LU1093756168.USD","AFG","LU1093756325.SGD","BHVN","BK4178"],"gpt_icon":0},{"id":"2524620415","title":"Xenon Pharmaceuticals to Present Promising Azetukalner Data at AAN 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524620415","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524620415?lang=en_us&edition=fundamental","pubTime":"2025-04-04 21:10","pubTimestamp":1743772201,"startTime":"0","endTime":"0","summary":"Xenon ( ($XENE) ) just unveiled an update. Xenon Pharmaceuticals announced that it will present long-term data on its drug azetukalner at the Ameri...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/xenon-pharmaceuticals-to-present-promising-azetukalner-data-at-aan-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/xenon-pharmaceuticals-to-present-promising-azetukalner-data-at-aan-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AAN","BK4178","XENE"],"gpt_icon":0},{"id":"2524204220","title":"NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2524204220","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524204220?lang=en_us&edition=fundamental","pubTime":"2025-04-04 21:10","pubTimestamp":1743772200,"startTime":"0","endTime":"0","summary":"Two presentations in the General Neurology and Late Breaker sessions will respectively cover new clinical and microRNA data from NeuroSense. Jeremy Shefner, M.D., Ph.D., Chair of the Department of Neurology and Senior Vice President at the Barrow Neurological Institute, will present new, compelling data from the Phase 2b trial of PrimeC, NeuroSense's novel investigational therapy for amyotrophic lateral sclerosis , at 2:24 p.m. His presentation, \"Shifting the Paradigm: PrimeC, an Oral Candidate for ALS, Demonstrates Safety, Efficacy, and Target Engagement in an 18-Month Phase 2b Trial,\" will highlight PrimeC's disease-modifying potential in ALS treatment.\"This exciting Phase 2b trial data underscores PrimeC's potential to redefine ALS treatment,\" says Shefner. \"By demonstrating safety and tolerability, an indication of marked reduction in ALS progression, and multiple biomarker endpoints establishing PrimeC's biological activity, we move closer to offering a disease-modifying therapy t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/neurosense-therapeutics-present-data-primecs-131000174.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurosense-therapeutics-present-data-primecs-131000174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AFG","BK4178","NRSNW","AAN","BK4117","LENZ","BK4107","BK4139","NRSN"],"gpt_icon":0},{"id":"2524087209","title":"Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524087209","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524087209?lang=en_us&edition=fundamental","pubTime":"2025-04-04 20:30","pubTimestamp":1743769800,"startTime":"0","endTime":"0","summary":"Three epilepsy posters to be presented in scientific sessions at the American Academy of Neurology meeting. Long-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in focal onset seizures . Exploratory analysis of efficacy of azetukalner in FOS seizure sub-types. Patient survey findings on mental health and comorbidity burdens of FOS. “Building upon more than 700+ patient-years of data to date, we are excited to share our 36-month azetukalner data from our ongoing X-TOLE open-label extension study in FOS showing sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and a consistent AE safety profile suggesting long-term efficacy and tolerability of azetukalner,” stated Dr. Christopher Kenney, Chief Medical Officer of Xenon. “We are also presenting an exploratory analysis from our XTOLE study showing reduced seizure frequency rate across four focal seizure subtypes. These promising data sets support our conviction that azetukalner may offer","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xenon-showcase-long-term-36-123000056.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","AAN","BK4178","XENE"],"gpt_icon":0},{"id":"2524120865","title":"Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2524120865","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524120865?lang=en_us&edition=fundamental","pubTime":"2025-04-04 19:00","pubTimestamp":1743764400,"startTime":"0","endTime":"0","summary":"Late-breaking oral presentation of results from the positive pivotal ACCORD-2 Phase 3 trial of AXS-05 in Alzheimer’s disease agitation Presentation featuring network meta-analysis of SYMBRAVO versus o","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/04/3055865/33090/en/Axsome-Therapeutics-Presents-Positive-Pivotal-Phase-3-Results-of-the-ACCORD-2-Trial-of-AXS-05-in-Alzheimer-s-Disease-Agitation-and-the-SYMPHONY-Trial-of-AXS-12-in-Narcolepsy-at-the.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXS","AAN","AXSM","AFG"],"gpt_icon":0},{"id":"2524495212","title":"Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2524495212","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524495212?lang=en_us&edition=fundamental","pubTime":"2025-04-04 06:18","pubTimestamp":1743718680,"startTime":"0","endTime":"0","summary":"Oral Plenary Presentation on Tuesday, April 8 Features Phase 3 Data for ANX005, the First Potential Targeted Therapy for GBS, Showing Rapid and Durable Benefit Across Clinical Measures and Time Points","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/03/3055669/0/en/Annexon-Highlights-Leadership-in-Advancing-Clinical-Research-and-Education-for-Guillain-Barr%C3%A9-Syndrome-GBS-at-American-Academy-of-Neurology-AAN-2025-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AFG","BK4178","BK4107","BK4117","GBSG","AAN","ANNX"],"gpt_icon":0},{"id":"2524325501","title":"NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2524325501","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524325501?lang=en_us&edition=fundamental","pubTime":"2025-04-03 20:00","pubTimestamp":1743681600,"startTime":"0","endTime":"0","summary":"Three-year data from NeuroPace’s Post-Approval Study of the RNS System in drug-resistant focal epilepsy to be shared in oral presentation. MOUNTAIN VIEW, Calif., April 03, 2025  -- NeuroPace, Inc. , a medical device company focused on transforming the lives of people living with epilepsy, will be attending and presenting at the upcoming American Academy of Neurology  2025 Annual Meeting, which is being held in San Diego from April 5 – 9. This includes an oral presentation on data from the Post-Approval Study  of the RNS System in adults treated with brain-responsive stimulation for drug-resistant focal epilepsy  on Monday, April 7.“Drug-resistant focal epilepsy means patients do not respond to drug therapy and often face a lifetime of debilitating seizures from the time of childhood or adolescence,” said Joel Becker, NeuroPace’s Chief Executive Officer. “It remains a significant unmet medical need, and we are committed to helping people with DRE. We look forward to sharing insights and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuropace-announces-upcoming-oral-presentation-120000175.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4212","BK4082","AAN","BK4171","BK4539","POST","DRE","NPCE","BK4178"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":38,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-10-04","symbol":"AAN","reason":null,"defaultRemindTime":1728048600000,"announcedDate":"2024-09-20","type":"delisting","dateTimestamp":1728014400000},{"date":"2024-09-13","symbol":"AAN","amount":0.125,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-13","defaultRemindTime":1726234200000,"name":"The Aaron's Company, Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-10-03","payableDate":"2024-09-13","currency":"USD","dateTimestamp":1726200000000,"payDate":"2024-10-03"},{"date":"2024-08-05","symbol":"AAN","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/06","expectedEps":0.03,"defaultRemindTime":1722888000000,"name":null,"time":"Post Market","dateTimestamp":1722830400000,"actualEps":null},{"date":"2024-06-14","symbol":"AAN","amount":0.125,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-06-14","defaultRemindTime":1718371800000,"name":"The Aaron's Company, Inc.","recordDate":"2024-07-03","payableDate":"2024-06-14","currency":"USD","dateTimestamp":1718337600000,"payDate":"2024-07-03"},{"date":"2024-05-06","symbol":"AAN","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/03","expectedEps":-0.08,"defaultRemindTime":1715025600000,"name":null,"time":"Post Market","dateTimestamp":1714968000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAN\",market:\"US\",,,undefined,":[{"executeDate":"2017-03-13","recordDate":null,"paymentDate":null,"value":0.0275,"currency":"USD"},{"executeDate":"2017-06-23","recordDate":null,"paymentDate":null,"value":0.0275,"currency":"USD"},{"executeDate":"2017-09-14","recordDate":null,"paymentDate":null,"value":0.0275,"currency":"USD"},{"executeDate":"2017-12-12","recordDate":null,"paymentDate":null,"value":0.03,"currency":"USD"},{"executeDate":"2018-03-22","recordDate":null,"paymentDate":null,"value":0.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":7,"updateTime":1720670400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AAN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AAN","date":"2024-10-02","current":-7.155926,"percent":0.311436,"low":-226.61145,"twenty":-13.023365,"median":6.536302,"eighty":20.725985,"high":112.497555,"avg":-0.454661,"sd":44.674017,"marketCap":304670698},"quantilePoints":[{"date":"2020-04-24","current":55.174309,"twenty":12.600629,"median":14.487214,"eighty":39.488526,"marketCap":1736445840},{"date":"2020-05-01","current":65.500706,"twenty":12.61139,"median":14.504533,"eighty":46.359785,"marketCap":2061438232},{"date":"2020-05-08","current":-7.937042,"twenty":12.622151,"median":14.571174,"eighty":48.522958,"marketCap":2417710345},{"date":"2020-05-15","current":-6.943248,"twenty":12.643672,"median":14.61603,"eighty":50.155943,"marketCap":2114989765},{"date":"2020-05-22","current":-7.53775,"twenty":12.65228,"median":14.634494,"eighty":50.708839,"marketCap":2296081540},{"date":"2020-05-29","current":-8.187709,"twenty":12.66261,"median":14.649576,"eighty":52.834231,"marketCap":2494066205},{"date":"2020-06-05","current":-10.108748,"twenty":12.666915,"median":14.697246,"eighty":55.285946,"marketCap":3079235898},{"date":"2020-06-12","current":-9.660654,"twenty":12.694892,"median":14.714231,"eighty":60.33638,"marketCap":2942741350},{"date":"2020-06-19","current":-9.374494,"twenty":12.706944,"median":14.728744,"eighty":64.235874,"marketCap":2855574041},{"date":"2020-06-26","current":-9.831462,"twenty":12.727173,"median":14.743696,"eighty":68.885595,"marketCap":2994771450},{"date":"2020-07-02","current":-9.922412,"twenty":12.757734,"median":14.760452,"eighty":74.680396,"marketCap":3022475789},{"date":"2020-07-10","current":-9.718329,"twenty":12.780116,"median":14.769223,"eighty":82.671415,"marketCap":2960309955},{"date":"2020-07-17","current":-9.76935,"twenty":12.808093,"median":14.806954,"eighty":91.048411,"marketCap":2975851414},{"date":"2020-07-24","current":-9.968996,"twenty":12.82574,"median":14.866761,"eighty":-10.859861,"marketCap":3036665816},{"date":"2020-07-31","current":-12.701825,"twenty":12.834349,"median":14.893301,"eighty":-10.268021,"marketCap":3542335892},{"date":"2020-08-07","current":-13.074984,"twenty":12.839514,"median":14.903566,"eighty":-10.577251,"marketCap":3646403759},{"date":"2020-08-14","current":-14.062047,"twenty":12.883417,"median":15.075972,"eighty":-10.859861,"marketCap":3921680051},{"date":"2020-08-21","current":-13.655185,"twenty":12.929473,"median":15.897669,"eighty":-11.826229,"marketCap":3808212506},{"date":"2020-08-28","current":-13.703334,"twenty":12.954868,"median":16.208979,"eighty":-12.506339,"marketCap":3821640618},{"date":"2020-09-04","current":-13.39277,"twenty":12.981123,"median":16.624181,"eighty":-12.566525,"marketCap":3735029297},{"date":"2020-09-11","current":-14.247423,"twenty":12.992314,"median":17.026732,"eighty":-12.622378,"marketCap":3973378281},{"date":"2020-09-18","current":-13.662407,"twenty":13.056878,"median":17.41088,"eighty":-12.80968,"marketCap":3810226723},{"date":"2020-09-25","current":-13.096651,"twenty":13.174383,"median":17.72832,"eighty":-13.012871,"marketCap":3652446409},{"date":"2020-10-02","current":-13.525181,"twenty":13.207096,"median":17.868637,"eighty":-13.083651,"marketCap":3771956604},{"date":"2020-10-09","current":-14.379834,"twenty":13.214843,"median":33.338326,"eighty":-13.117837,"marketCap":4010305589},{"date":"2020-10-16","current":-14.322055,"twenty":13.224312,"median":38.979544,"eighty":-13.152023,"marketCap":3994191854},{"date":"2020-10-23","current":-14.134272,"twenty":13.267355,"median":41.25936,"eighty":-13.164982,"marketCap":3941822218},{"date":"2020-10-30","current":-13.18332,"twenty":13.431346,"median":46.359785,"eighty":-13.174612,"marketCap":3676617010},{"date":"2020-11-06","current":-13.890074,"twenty":13.510113,"median":48.066995,"eighty":-13.16406,"marketCap":3873719412},{"date":"2020-11-13","current":-18.86588,"twenty":13.554877,"median":49.399254,"eighty":-13.174612,"marketCap":3949383272},{"date":"2020-11-20","current":-20.234189,"twenty":13.740165,"median":50.045957,"eighty":-13.179304,"marketCap":4235825028},{"date":"2020-11-27","current":-3.0341,"twenty":12.60063,"median":14.406704,"eighty":14.852959,"marketCap":753260750},{"date":"2020-12-04","current":-2.585107,"twenty":12.532192,"median":14.373349,"eighty":14.823056,"marketCap":641791671},{"date":"2020-12-11","current":-2.410953,"twenty":12.484845,"median":14.29399,"eighty":14.806494,"marketCap":598555179},{"date":"2020-12-18","current":-2.470818,"twenty":12.40823,"median":14.223831,"eighty":14.790852,"marketCap":613417723},{"date":"2020-12-24","current":-2.283058,"twenty":12.321715,"median":14.182426,"eighty":14.77668,"marketCap":566803381},{"date":"2020-12-31","current":-2.579665,"twenty":12.263178,"median":14.155973,"eighty":14.768028,"marketCap":640440530},{"date":"2021-01-08","current":-2.747017,"twenty":-12.767253,"median":12.412319,"eighty":14.892168,"marketCap":681988096},{"date":"2021-01-15","current":-2.921171,"twenty":-12.676425,"median":12.394026,"eighty":14.876492,"marketCap":725224588},{"date":"2021-01-22","current":-2.816406,"twenty":-12.623461,"median":12.34668,"eighty":14.868142,"marketCap":699215136},{"date":"2021-01-29","current":-2.304827,"twenty":-12.566525,"median":12.314398,"eighty":14.85756,"marketCap":572207942},{"date":"2021-02-05","current":-2.670824,"twenty":-12.506339,"median":12.260595,"eighty":14.829956,"marketCap":663072131},{"date":"2021-02-12","current":-2.717084,"twenty":-11.826229,"median":12.245531,"eighty":14.807414,"marketCap":674556824},{"date":"2021-02-19","current":-2.880354,"twenty":-10.895798,"median":12.221858,"eighty":14.800053,"marketCap":715091035},{"date":"2021-02-26","current":-2.824769,"twenty":-10.664651,"median":12.178815,"eighty":14.779165,"marketCap":751139845},{"date":"2021-03-05","current":-3.082033,"twenty":-10.291535,"median":12.103491,"eighty":14.768028,"marketCap":819549667},{"date":"2021-03-12","current":-3.265978,"twenty":-10.182396,"median":11.879671,"eighty":14.76305,"marketCap":868462690},{"date":"2021-03-19","current":-3.326435,"twenty":-10.119396,"median":-2.281017,"eighty":14.761535,"marketCap":884538998},{"date":"2021-03-26","current":-3.343157,"twenty":-10.105642,"median":-2.304827,"eighty":14.756348,"marketCap":888985636},{"date":"2021-04-01","current":-3.34573,"twenty":-10.09322,"median":-2.344284,"eighty":14.747146,"marketCap":889669735},{"date":"2021-04-09","current":-3.17079,"twenty":-10.071037,"median":-2.386462,"eighty":14.740245,"marketCap":843151056},{"date":"2021-04-16","current":-3.285273,"twenty":-10.046636,"median":-2.443607,"eighty":14.729751,"marketCap":873593426},{"date":"2021-04-23","current":-3.316144,"twenty":-10.020017,"median":-2.447688,"eighty":14.728744,"marketCap":881802605},{"date":"2021-04-30","current":11.206787,"twenty":-9.991179,"median":-2.446328,"eighty":14.725108,"marketCap":1055511238},{"date":"2021-05-07","current":11.685679,"twenty":-9.968996,"median":-2.40415,"eighty":14.71582,"marketCap":1100615635},{"date":"2021-05-14","current":11.816285,"twenty":-9.960123,"median":-2.352448,"eighty":14.712642,"marketCap":1112916834},{"date":"2021-05-21","current":12.614438,"twenty":-9.922412,"median":-2.317753,"eighty":14.704211,"marketCap":1188090830},{"date":"2021-05-28","current":13.049794,"twenty":-9.922412,"median":-2.283058,"eighty":14.697246,"marketCap":1229094828},{"date":"2021-06-04","current":13.125981,"twenty":-9.917088,"median":-2.227274,"eighty":14.68932,"marketCap":1236270527},{"date":"2021-06-11","current":13.260216,"twenty":-9.867842,"median":11.159624,"eighty":14.667402,"marketCap":1248913426},{"date":"2021-06-18","current":12.57453,"twenty":-9.84699,"median":11.239439,"eighty":14.64187,"marketCap":1184332130},{"date":"2021-06-25","current":11.965032,"twenty":-9.834124,"median":11.357348,"eighty":14.634991,"marketCap":1126926534},{"date":"2021-07-02","current":11.732842,"twenty":-9.829688,"median":11.551444,"eighty":14.634457,"marketCap":1105057735},{"date":"2021-07-09","current":11.174135,"twenty":-9.803955,"median":11.36279,"eighty":14.630291,"marketCap":1052435938},{"date":"2021-07-16","current":10.038588,"twenty":-9.784434,"median":11.319254,"eighty":14.62063,"marketCap":945484414},{"date":"2021-07-23","current":9.724994,"twenty":-9.774674,"median":11.228555,"eighty":14.598088,"marketCap":915948515},{"date":"2021-07-30","current":9.001746,"twenty":-9.75604,"median":11.175949,"eighty":14.583366,"marketCap":943256951},{"date":"2021-08-06","current":8.621347,"twenty":-9.731195,"median":11.141484,"eighty":14.569104,"marketCap":903396422},{"date":"2021-08-13","current":9.117113,"twenty":-9.719216,"median":10.680732,"eighty":14.542881,"marketCap":955345800},{"date":"2021-08-20","current":8.764776,"twenty":-9.702358,"median":10.238148,"eighty":14.515087,"marketCap":918425802},{"date":"2021-08-27","current":8.602638,"twenty":-9.686386,"median":10.004734,"eighty":14.503803,"marketCap":901436068},{"date":"2021-09-03","current":8.371904,"twenty":-9.670858,"median":9.878227,"eighty":14.495035,"marketCap":877258370},{"date":"2021-09-10","current":8.178587,"twenty":-9.661985,"median":9.724994,"eighty":14.487674,"marketCap":857001379},{"date":"2021-09-17","current":8.396849,"twenty":-9.651781,"median":9.151412,"eighty":14.481233,"marketCap":879872175},{"date":"2021-09-24","current":8.580812,"twenty":-9.63226,"median":9.001746,"eighty":14.46099,"marketCap":899148988},{"date":"2021-10-01","current":8.761658,"twenty":-9.601647,"median":8.958094,"eighty":14.437068,"marketCap":918099076},{"date":"2021-10-08","current":8.714887,"twenty":-9.542197,"median":8.892615,"eighty":14.434307,"marketCap":913198191},{"date":"2021-10-15","current":8.56834,"twenty":-9.495613,"median":8.813105,"eighty":14.433387,"marketCap":897842086},{"date":"2021-10-22","current":9.447624,"twenty":-9.47343,"median":8.883261,"eighty":14.431087,"marketCap":989978719},{"date":"2021-10-29","current":7.629357,"twenty":-9.434388,"median":8.8209,"eighty":14.420506,"marketCap":736393147},{"date":"2021-11-05","current":8.350215,"twenty":-9.394459,"median":8.792838,"eighty":14.39847,"marketCap":805971123},{"date":"2021-11-12","current":8.568756,"twenty":-9.349649,"median":8.764776,"eighty":14.382391,"marketCap":827064898},{"date":"2021-11-19","current":8.239314,"twenty":-9.109187,"median":8.724241,"eighty":14.37404,"marketCap":795266819},{"date":"2021-11-26","current":7.847898,"twenty":-8.748937,"median":8.714887,"eighty":14.357938,"marketCap":757486922},{"date":"2021-12-03","current":7.440172,"twenty":-8.524445,"median":8.691502,"eighty":14.306872,"marketCap":718132864},{"date":"2021-12-10","current":7.94249,"twenty":-8.467214,"median":8.668117,"eighty":14.283409,"marketCap":766617064},{"date":"2021-12-17","current":7.844636,"twenty":-8.262243,"median":8.662471,"eighty":14.239703,"marketCap":757172090},{"date":"2021-12-23","current":7.988155,"twenty":-8.187709,"median":8.61667,"eighty":14.234182,"marketCap":771024719},{"date":"2021-12-31","current":8.040344,"twenty":-8.054612,"median":8.608874,"eighty":14.21348,"marketCap":776062038},{"date":"2022-01-07","current":7.74352,"twenty":-8.039083,"median":8.604197,"eighty":14.188176,"marketCap":747412283},{"date":"2022-01-14","current":7.489099,"twenty":-7.937042,"median":8.587048,"eighty":14.176675,"marketCap":722855351},{"date":"2022-01-21","current":6.954164,"twenty":-7.711664,"median":8.580812,"eighty":14.163793,"marketCap":671222826},{"date":"2022-01-28","current":6.771503,"twenty":-7.561264,"median":8.568548,"eighty":14.153212,"marketCap":653592207},{"date":"2022-02-04","current":6.774764,"twenty":-7.498708,"median":8.50598,"eighty":14.13849,"marketCap":653907040},{"date":"2022-02-11","current":6.800859,"twenty":-7.4783,"median":8.402672,"eighty":14.109507,"marketCap":656425699},{"date":"2022-02-18","current":6.85631,"twenty":-7.417075,"median":8.390613,"eighty":14.090805,"marketCap":661777851},{"date":"2022-02-25","current":6.0444,"twenty":-7.399772,"median":8.371904,"eighty":14.073473,"marketCap":664485049},{"date":"2022-03-04","current":6.303647,"twenty":-7.338104,"median":8.35837,"eighty":14.046019,"marketCap":692985107},{"date":"2022-03-11","current":6.154298,"twenty":-7.214323,"median":8.322016,"eighty":14.028536,"marketCap":676566596},{"date":"2022-03-18","current":6.531897,"twenty":-7.133134,"median":8.300596,"eighty":14.016575,"marketCap":718077550},{"date":"2022-03-25","current":6.358874,"twenty":-7.012459,"median":8.278364,"eighty":13.990352,"marketCap":699056405},{"date":"2022-04-01","current":5.853417,"twenty":-6.728961,"median":8.262316,"eighty":13.959988,"marketCap":643489564},{"date":"2022-04-08","current":6.111955,"twenty":-4.797768,"median":8.237829,"eighty":13.929624,"marketCap":671911684},{"date":"2022-04-14","current":6.210723,"twenty":-3.54381,"median":8.229529,"eighty":13.89558,"marketCap":682769573},{"date":"2022-04-22","current":5.94928,"twenty":-3.437831,"median":8.209791,"eighty":13.857395,"marketCap":654028103},{"date":"2022-04-29","current":6.626359,"twenty":-3.415191,"median":8.180601,"eighty":13.79395,"marketCap":630451705},{"date":"2022-05-06","current":6.539213,"twenty":-3.410303,"median":8.142587,"eighty":13.634075,"marketCap":622160328},{"date":"2022-05-13","current":6.452066,"twenty":-3.405158,"median":8.086009,"eighty":13.512696,"marketCap":613868951},{"date":"2022-05-20","current":5.864635,"twenty":-3.380718,"median":8.051782,"eighty":13.496451,"marketCap":557978932},{"date":"2022-05-27","current":6.077659,"twenty":-3.349589,"median":8.001202,"eighty":13.451527,"marketCap":578246741},{"date":"2022-06-03","current":5.961464,"twenty":-3.34573,"median":7.971846,"eighty":13.396862,"marketCap":567191572},{"date":"2022-06-10","current":5.796854,"twenty":-3.345215,"median":7.947382,"eighty":13.321166,"marketCap":551530083},{"date":"2022-06-17","current":5.060951,"twenty":-3.339813,"median":7.90661,"eighty":13.254413,"marketCap":481514015},{"date":"2022-06-24","current":5.222333,"twenty":-3.326435,"median":7.860945,"eighty":13.231199,"marketCap":496868416},{"date":"2022-07-01","current":4.760779,"twenty":-3.316144,"median":7.81528,"eighty":13.22259,"marketCap":452954829},{"date":"2022-07-08","current":4.947983,"twenty":-3.305854,"median":7.76146,"eighty":13.21226,"marketCap":470765934},{"date":"2022-07-15","current":4.734958,"twenty":-3.289903,"median":7.704378,"eighty":13.206235,"marketCap":450498125},{"date":"2022-07-22","current":5.167463,"twenty":-3.28553,"median":7.670129,"eighty":13.197004,"marketCap":491647920},{"date":"2022-07-29","current":7.051656,"twenty":-3.278069,"median":7.648928,"eighty":13.194912,"marketCap":400717386},{"date":"2022-08-05","current":7.214136,"twenty":-3.275239,"median":7.552705,"eighty":13.171694,"marketCap":409950505},{"date":"2022-08-12","current":7.907387,"twenty":-3.267779,"median":7.629357,"eighty":13.156156,"marketCap":449345149},{"date":"2022-08-19","current":7.598674,"twenty":-3.244368,"median":7.653821,"eighty":13.131529,"marketCap":431802221},{"date":"2022-08-26","current":6.932503,"twenty":-3.236907,"median":7.598674,"eighty":13.111469,"marketCap":393946432},{"date":"2022-09-02","current":6.428814,"twenty":-3.219927,"median":7.549929,"eighty":13.107841,"marketCap":365323761},{"date":"2022-09-09","current":6.640038,"twenty":-3.21118,"median":7.533133,"eighty":13.099134,"marketCap":377326816},{"date":"2022-09-16","current":6.612958,"twenty":-3.207321,"median":7.484937,"eighty":13.091152,"marketCap":375787963},{"date":"2022-09-23","current":5.8493,"twenty":-3.205263,"median":7.456481,"eighty":13.087524,"marketCap":332392302},{"date":"2022-09-30","current":5.26437,"twenty":-3.201919,"median":7.440172,"eighty":13.068659,"marketCap":299153071},{"date":"2022-10-07","current":5.145217,"twenty":-3.198832,"median":7.301545,"eighty":13.052696,"marketCap":292382117},{"date":"2022-10-14","current":4.798592,"twenty":-3.190085,"median":7.23794,"eighty":13.04544,"marketCap":272684795},{"date":"2022-10-21","current":4.717352,"twenty":-3.17645,"median":7.204836,"eighty":13.012404,"marketCap":268068236},{"date":"2022-10-28","current":18.856739,"twenty":-3.156126,"median":7.23794,"eighty":13.087524,"marketCap":317962337},{"date":"2022-11-04","current":17.72497,"twenty":-3.141719,"median":7.301545,"eighty":13.115097,"marketCap":298878441},{"date":"2022-11-11","current":20.882972,"twenty":-3.13786,"median":7.440172,"eighty":13.194912,"marketCap":352128668},{"date":"2022-11-18","current":20.171052,"twenty":-3.129627,"median":7.456481,"eighty":13.226034,"marketCap":340124281},{"date":"2022-11-25","current":21.138532,"twenty":-3.119851,"median":7.477233,"eighty":13.381747,"marketCap":356437935},{"date":"2022-12-02","current":22.945713,"twenty":-3.112391,"median":7.528241,"eighty":13.634075,"marketCap":386910608},{"date":"2022-12-09","current":21.412348,"twenty":-3.103901,"median":7.549929,"eighty":13.936064,"marketCap":361055006},{"date":"2022-12-16","current":21.722672,"twenty":-3.091295,"median":7.598674,"eighty":14.030377,"marketCap":366287688},{"date":"2022-12-23","current":20.755191,"twenty":-3.086664,"median":7.653821,"eighty":14.122388,"marketCap":349974034},{"date":"2022-12-30","current":21.813943,"twenty":-3.077344,"median":7.683177,"eighty":14.173455,"marketCap":367826712},{"date":"2023-01-06","current":23.821921,"twenty":-3.05859,"median":7.720687,"eighty":14.234182,"marketCap":401685237},{"date":"2023-01-13","current":26.194986,"twenty":-3.050427,"median":7.750322,"eighty":14.369899,"marketCap":441699859},{"date":"2023-01-20","current":25.884662,"twenty":-3.037365,"median":7.785923,"eighty":14.411305,"marketCap":436467178},{"date":"2023-01-27","current":26.158478,"twenty":-2.983948,"median":7.846267,"eighty":14.435227,"marketCap":441084249},{"date":"2023-02-03","current":28.239473,"twenty":-2.934484,"median":7.860945,"eighty":14.492274,"marketCap":476173994},{"date":"2023-02-10","current":26.724362,"twenty":-2.921987,"median":7.903348,"eighty":14.564964,"marketCap":450626197},{"date":"2023-02-17","current":26.92516,"twenty":-2.910286,"median":7.907387,"eighty":14.628911,"marketCap":454012050},{"date":"2023-02-24","current":25.793391,"twenty":-2.891238,"median":7.922919,"eighty":14.647007,"marketCap":434928154},{"date":"2023-03-03","current":-74.11349,"twenty":-2.922804,"median":7.915153,"eighty":14.672386,"marketCap":391319229},{"date":"2023-03-10","current":-64.718823,"twenty":-3.053692,"median":7.907387,"eighty":14.647007,"marketCap":341715383},{"date":"2023-03-17","current":-54.86022,"twenty":-3.100042,"median":7.890196,"eighty":14.635427,"marketCap":289661964},{"date":"2023-03-24","current":-55.522605,"twenty":-3.13786,"median":7.853226,"eighty":14.634482,"marketCap":293159356},{"date":"2023-03-31","current":-58.235436,"twenty":-3.190085,"median":7.835391,"eighty":14.630291,"marketCap":307483103},{"date":"2023-04-06","current":-57.512015,"twenty":-3.205778,"median":7.782661,"eighty":14.622931,"marketCap":303663437},{"date":"2023-04-14","current":-64.62566,"twenty":-3.237936,"median":7.74352,"eighty":14.604068,"marketCap":341223485},{"date":"2023-04-21","current":-62.214255,"twenty":-3.281671,"median":7.694593,"eighty":14.584286,"marketCap":328491265},{"date":"2023-04-28","current":-29.179552,"twenty":-3.322319,"median":7.658713,"eighty":14.573245,"marketCap":408922246},{"date":"2023-05-05","current":-26.224103,"twenty":-3.349589,"median":7.614015,"eighty":14.548861,"marketCap":367504573},{"date":"2023-05-12","current":-27.701827,"twenty":-3.415191,"median":7.555345,"eighty":14.520365,"marketCap":388213410},{"date":"2023-05-19","current":-28.650218,"twenty":-6.80039,"median":7.533133,"eighty":14.504046,"marketCap":401504155},{"date":"2023-05-26","current":-27.282771,"twenty":-7.358069,"median":7.484937,"eighty":14.497795,"marketCap":382340755},{"date":"2023-06-02","current":-27.018104,"twenty":-7.486286,"median":7.459743,"eighty":14.488594,"marketCap":378631709},{"date":"2023-06-09","current":-31.782113,"twenty":-8.018675,"median":7.446307,"eighty":14.483074,"marketCap":445394525},{"date":"2023-06-16","current":-30.017665,"twenty":-8.467214,"median":7.348842,"eighty":14.468351,"marketCap":420667556},{"date":"2023-06-23","current":-28.716385,"twenty":-9.312382,"median":7.241202,"eighty":14.438908,"marketCap":402431417},{"date":"2023-06-30","current":-31.605668,"twenty":-9.459233,"median":7.224968,"eighty":14.435227,"marketCap":442921828},{"date":"2023-07-07","current":-31.892391,"twenty":-9.591,"median":7.195537,"eighty":14.434307,"marketCap":446939961},{"date":"2023-07-14","current":-33.083393,"twenty":-9.670858,"median":7.136824,"eighty":14.432927,"marketCap":463630665},{"date":"2023-07-21","current":-34.340562,"twenty":-9.731195,"median":7.111232,"eighty":14.430627,"marketCap":481248630},{"date":"2023-07-28","current":-33.921505,"twenty":-9.803955,"median":7.051837,"eighty":14.415905,"marketCap":475375975},{"date":"2023-08-04","current":-188.365396,"twenty":-9.879821,"median":7.029992,"eighty":14.394353,"marketCap":405927428},{"date":"2023-08-11","current":-189.224858,"twenty":-9.963672,"median":6.998198,"eighty":14.380528,"marketCap":407779569},{"date":"2023-08-18","current":-177.90861,"twenty":-10.056396,"median":6.986782,"eighty":14.372659,"marketCap":383393054},{"date":"2023-08-25","current":-170.316697,"twenty":-10.152227,"median":6.952533,"eighty":14.334015,"marketCap":367032481},{"date":"2023-09-01","current":-172.895082,"twenty":-11.528064,"median":6.932503,"eighty":14.300431,"marketCap":372588902},{"date":"2023-09-08","current":-145.392302,"twenty":-12.623461,"median":6.905237,"eighty":14.272827,"marketCap":313320410},{"date":"2023-09-15","current":-149.25988,"twenty":-13.033575,"median":6.884571,"eighty":14.238323,"marketCap":321655042},{"date":"2023-09-22","current":-152.697728,"twenty":-13.168875,"median":6.85631,"eighty":14.225901,"marketCap":329063603},{"date":"2023-09-29","current":-152.41124,"twenty":-13.297434,"median":6.830215,"eighty":14.203358,"marketCap":328446223},{"date":"2023-10-06","current":-140.665261,"twenty":-13.435141,"median":6.802519,"eighty":14.183576,"marketCap":303133638},{"date":"2023-10-13","current":-136.797683,"twenty":-13.525181,"median":6.773134,"eighty":14.170234,"marketCap":294799007},{"date":"2023-10-20","current":-133.646323,"twenty":-13.584405,"median":6.745664,"eighty":14.158733,"marketCap":288007825},{"date":"2023-10-27","current":23.778109,"twenty":-13.598368,"median":6.745664,"eighty":14.167014,"marketCap":221707087},{"date":"2023-11-03","current":23.680524,"twenty":-13.577664,"median":6.774764,"eighty":14.236942,"marketCap":220797209},{"date":"2023-11-10","current":22.346868,"twenty":-13.547812,"median":6.803199,"eighty":14.372659,"marketCap":208362201},{"date":"2023-11-17","current":27.909189,"twenty":-13.52807,"median":6.836739,"eighty":14.430627,"marketCap":260225282},{"date":"2023-11-24","current":28.917563,"twenty":-13.525181,"median":6.85631,"eighty":14.437068,"marketCap":269627361},{"date":"2023-12-01","current":28.657338,"twenty":-13.505446,"median":6.884571,"eighty":14.497795,"marketCap":267201018},{"date":"2023-12-08","current":34.02449,"twenty":-13.470998,"median":6.905237,"eighty":14.573245,"marketCap":317244342},{"date":"2023-12-15","current":38.123042,"twenty":-13.460384,"median":6.940627,"eighty":14.631672,"marketCap":355459243},{"date":"2023-12-22","current":36.333991,"twenty":-13.435141,"median":6.954164,"eighty":14.677371,"marketCap":338778135},{"date":"2023-12-29","current":36.333991,"twenty":-13.404807,"median":6.970474,"eighty":14.704211,"marketCap":338778135},{"date":"2024-01-05","current":36.952027,"twenty":-13.397585,"median":6.991083,"eighty":14.719535,"marketCap":344540700},{"date":"2024-01-12","current":35.423202,"twenty":-13.386992,"median":7.016542,"eighty":14.743005,"marketCap":330285935},{"date":"2024-01-19","current":33.308869,"twenty":-13.35425,"median":7.040824,"eighty":14.762852,"marketCap":310571898},{"date":"2024-01-26","current":34.870223,"twenty":-13.297434,"median":7.052018,"eighty":14.7972,"marketCap":325129956},{"date":"2024-02-02","current":33.66668,"twenty":-13.239655,"median":7.119356,"eighty":14.868142,"marketCap":313908120},{"date":"2024-02-09","current":33.991961,"twenty":-13.181312,"median":7.140086,"eighty":14.902766,"marketCap":316941049},{"date":"2024-02-16","current":35.228033,"twenty":-13.176456,"median":7.204836,"eighty":15.530992,"marketCap":328466178},{"date":"2024-02-23","current":33.146228,"twenty":-13.171283,"median":7.231454,"eighty":16.007704,"marketCap":309055434},{"date":"2024-03-01","current":83.351439,"twenty":-13.159245,"median":7.254249,"eighty":16.944381,"marketCap":235301113},{"date":"2024-03-08","current":77.221075,"twenty":-13.139022,"median":7.397562,"eighty":17.504731,"marketCap":217995096},{"date":"2024-03-15","current":74.74742,"twenty":-13.092318,"median":7.453219,"eighty":17.739361,"marketCap":211011966},{"date":"2024-03-22","current":81.364368,"twenty":-13.05428,"median":7.477233,"eighty":17.972015,"marketCap":229691610},{"date":"2024-03-28","current":80.387995,"twenty":-12.971462,"median":7.50867,"eighty":18.290855,"marketCap":226935310},{"date":"2024-04-05","current":78.760708,"twenty":-12.865396,"median":7.544513,"eighty":18.783722,"marketCap":222341478},{"date":"2024-04-12","current":77.458878,"twenty":-12.701825,"median":7.583029,"eighty":19.185317,"marketCap":218666412},{"date":"2024-04-19","current":79.303137,"twenty":-12.659492,"median":7.648928,"eighty":20.171052,"marketCap":223872755},{"date":"2024-04-26","current":79.411623,"twenty":-12.569414,"median":7.683177,"eighty":20.718683,"marketCap":224179011},{"date":"2024-05-03","current":73.661874,"twenty":-12.562192,"median":7.736996,"eighty":20.882972,"marketCap":207947470},{"date":"2024-05-10","current":-9.41993,"twenty":-12.422559,"median":7.694593,"eighty":20.882972,"marketCap":227547821},{"date":"2024-05-17","current":-9.55939,"twenty":-10.931734,"median":7.658713,"eighty":20.755191,"marketCap":230916631},{"date":"2024-05-24","current":-9.064939,"twenty":-10.752052,"median":7.614015,"eighty":20.736937,"marketCap":218972668},{"date":"2024-05-31","current":-9.77492,"twenty":-10.40245,"median":7.561364,"eighty":20.736937,"marketCap":236122975},{"date":"2024-06-07","current":-10.751145,"twenty":-10.751145,"median":7.538026,"eighty":20.722334,"marketCap":259704647},{"date":"2024-06-14","current":-9.812955,"twenty":-10.735931,"median":7.489099,"eighty":20.685825,"marketCap":237041741},{"date":"2024-06-21","current":-13.023365,"twenty":-10.751689,"median":7.469528,"eighty":20.598203,"marketCap":314592404},{"date":"2024-06-28","current":-12.984217,"twenty":-10.787988,"median":7.459743,"eighty":20.532488,"marketCap":313646735},{"date":"2024-07-05","current":-13.036414,"twenty":-12.56797,"median":7.440172,"eighty":20.433914,"marketCap":314907627},{"date":"2024-07-12","current":-12.997266,"twenty":-12.950249,"median":7.23794,"eighty":20.433914,"marketCap":313961958},{"date":"2024-07-15","current":-13.036414,"twenty":-12.981666,"median":7.224968,"eighty":20.433914,"marketCap":314907627},{"date":"2024-08-02","current":-13.127761,"twenty":-13.007706,"median":7.086518,"eighty":20.725985,"marketCap":317114187},{"date":"2024-08-09","current":-7.228062,"twenty":-13.023365,"median":7.029992,"eighty":20.725985,"marketCap":307741975},{"date":"2024-08-16","current":-7.271344,"twenty":-13.023365,"median":6.970474,"eighty":20.725985,"marketCap":309584741},{"date":"2024-08-23","current":-7.26413,"twenty":-13.023365,"median":6.9205,"eighty":20.725985,"marketCap":309277614},{"date":"2024-08-30","current":-7.278558,"twenty":-13.023365,"median":6.879843,"eighty":20.725985,"marketCap":309891869},{"date":"2024-09-06","current":-7.206421,"twenty":-13.023365,"median":6.830215,"eighty":20.725985,"marketCap":306820592},{"date":"2024-09-13","current":-7.292985,"twenty":-13.023365,"median":6.773134,"eighty":20.725985,"marketCap":310506124},{"date":"2024-09-20","current":-7.242489,"twenty":-13.023365,"median":6.654179,"eighty":20.725985,"marketCap":308356230},{"date":"2024-09-27","current":-7.235276,"twenty":-13.023365,"median":6.602126,"eighty":20.725985,"marketCap":308049103},{"date":"2024-10-02","current":-7.155926,"twenty":-13.023365,"median":6.536302,"eighty":20.725985,"marketCap":304670698}],"updateTime":1745528159295}}}